Poly Medicure Limited has informed the Exchange regarding Change in Auditors of the company.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure's Board, at its meeting on August 8, 2025, approved Q1 FY26 unaudited financial results showing healthy growth. Standalone total income rose to Rs. 42,514 lakhs from Rs. 38,426 lakhs YoY, while standalone profit after tax climbed to Rs. 8,793 lakhs (from Rs. 7,230 lakhs). Consolidated PAT grew to Rs. 9,308 lakhs versus Rs. 7,404 lakhs last year, with consolidated EPS at Rs. 9.19. The Board re-appointed two Independent Directors — Mr. Amit Khosla and Ms. Sonal Mattoo — for five-year terms and appointed Mr. Pankaj Kumar Gupta (President - Operations, with over 17 years at the company) as Executive Director for five years. It also granted 3,400 stock options under ESOP 2020 at Rs. 100 per share and re-appointed M/s Jai Prakash & Company as Cost Auditors for FY25-26. The statutory auditor Doogar & Associates continues, issuing an unmodified review report.
Strong YoY earnings growth (~22% standalone PAT) signals operational momentum and may support the stock positively. The internal elevation of Mr. Gupta as Executive Director and continuity in the board and audit setup indicate stability rather than governance disruption.